past successes
We are excited to share our success
Pfizer B7471014
Pfizer B7471014
Started: 11/2020
Study Name: A phase 3, single-arm trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in healthy children 15 months through 17 years of age
Indication: Pneumococcal
Principal Investigators: Luke Anschutz, Dave Meduna
Forte Biosciences FB401-01
Started: 11/2020
Study Name: A randomized, double-blind, placebo-controlled, multicenter, 16-week trial to evaluate the efficacy and safety of xxx in children, adolescent and adult subjects (ages 2 years and older) with mild to moderate atopic dermatitis
Indication: Atopic Dermatitis
Principal Investigator: Sahra Niazi
Pfizer C3671008
Started: 3/2020
Study name: A phase 3, randomized, double- or observer-blinded, placebo-controlled trial to evaluate the efficacy and safety of a respiratory syncytial virus (rsv) perfusion subunit vaccine in infants born to women vaccinated during pregnancy
Indication: RSV/OB
Principal Investigator: Brad Brabec
Pfizer B7471011
Started: 2/2020
Study name: A phase 3, randomized, double-blind trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in healthy infants
Indication: Pneumococcal
Principal Investigators: Brad Brabec, Dave Meduna
Sanofi Pasteur MET59
Started: 9/2019
Study Name: Immunogenicity and Safety of a Booster Dose of an Investigational xxx Meningococcal Conjugate Vaccine in Adolescents and Adults
Indication: Meningitis
Principal Investigators: Paul Bernhardson, Brad Brabec, Steve Russell
Astra Zeneca Melody D5290C00004
Started: 9/2019
Study Name: A phase 3 randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of xxx, a monoclonal antibody with an extended half-life against respiratory syncytial virus, in healthy late preterm and term infants (melody)
Indication: RSV
Principal Investigator: Steve Russell
Kimberly Clark 39320.00
Started: 9/2019
Study name: A longitudinal study to evaluate various skin health biophysical measures preceding diaper dermatitis in newborns
Indication: None Specified Skin Study
Principal Investigator: Amy Bargen
Kimberly Clark 39322.00
Started: 9/2019
Study Name: An exploratory study to identify the composition of the microbiome of healthy diapered skin in eight to twelve month old infants.
Indication: None Specified Skin Study
Principal Investigator: Amy Bargen
Pfizer C3671003
Started: 9/2019
Study Name A phase 2b, randomized, placebo-controlled, observer-blinded trial to evaluate the safety, tolerability, and immunogenicity of a respiratory syncytial virus (rsv) vaccine in pregnant women 18 through 49years of age and their infants
Indication: RSV/OB
Principal Investigator: Brad Brabec
GSK ROTA-96
Started: 6/2019
Study Name: A phase III, observer-blind, randomized, multi-country study to assess the reactogenicity and safety of the Porcine circovirus (PCV) free liquid formulation of GSK’s oral live attenuated human rotavirus (HRV) vaccine as compared to the xxx the GSK’s HRV vaccine, when administered as a 2-dose vaccination in infants starting at age 6-12 weeks.
Indication: RSV
Principal Investigators: Sahra Niazi, Steve Russell, Pam Zegers
LOCATIONS
3262 Salt Creek Circle, Lincoln, NE 68504
4020 Hohensee Drive, Lincoln, NE 68516
8201 Northwoods Drive, Lincoln, NE 68505
1336 West A St, Suite B Lincoln, NE 68522
Phone: 402-465-5600
Fax: 402-327-6074
CONNECT
Phone: 402-465-5600
Fax: 402-327-6074
OFFICE HOURS
Clinic Hours-Weekdays
8:45 am to 4:30 pm Monday – Friday
Clinic Hours-Weekends
Northwoods and West A Locations Only
9:00 am to 4:00 pm Saturday
10:00 am to 2:00 pm Sunday
Clinic Hours-Evenings
West A Location Only
Monday – Thursday starting at 5:30 pm
Phone Hours
8:00 am to 5:00 pm Monday – Friday
8:30 am to 3:30 pm Saturday
9:30 am to 1:30 pm Sunday
After hours - call 402-465-5600 and choose option 1 to reach Telephone Line to Care.